CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancerErin M. Bange, John P. Reilly, Madison E. Weirick et al.|Nature Medicine|2021Cited by 519
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L. Garfall, Carl H. June|JCI Insight|2018Cited by 196
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomasGuido Ghilardi, Stephen J. Schuster, Elise A. Chong et al.|Annals of Oncology|2022Cited by 95